Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Ionis Pharmaceuticals Inc’s stock clocked out at $36.75, down -1.08% from its previous closing price of $37.15. In other words, the price has decreased by -$1.08 from its previous closing price. On the day, 1.49 million shares were traded. IONS stock price reached its highest trading level at $37.69 during the session, while it also had its lowest trading level at $35.85.
Ratios:
To gain a deeper understanding of IONS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.82 and its Current Ratio is at 8.91. In the meantime, Its Debt-to-Equity ratio is 3.00 whereas as Long-Term Debt/Eq ratio is at 2.93.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BMO Capital Markets on August 02, 2024, Downgraded its rating to Market Perform and sets its target price to $60 from $67 previously.
On July 24, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $53 to $62.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 12 ’24 when Swayze Eric sold 1,194 shares for $37.92 per share. The transaction valued at 45,278 led to the insider holds 33,713 shares of the business.
Monia Brett P sold 6,630 shares of IONS for $252,294 on Nov 12 ’24. The Chief Executive Officer now owns 167,393 shares after completing the transaction at $38.05 per share. On Nov 12 ’24, another insider, LOSCALZO JOSEPH, who serves as the Director of the company, sold 13,508 shares for $37.86 each. As a result, the insider received 511,426 and left with 32,251 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 5865887744 and an Enterprise Value of 5306540544. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.22 while its Price-to-Book (P/B) ratio in mrq is 8.75. Its current Enterprise Value per Revenue stands at 6.608 whereas that against EBITDA is -15.781.
Stock Price History:
Over the past 52 weeks, IONS has reached a high of $54.44, while it has fallen to a 52-week low of $33.33. The 50-Day Moving Average of the stock is -2.76%, while the 200-Day Moving Average is calculated to be -13.27%.
Shares Statistics:
It appears that IONS traded 1.69M shares on average per day over the past three months and 1579240 shares per day over the past ten days. A total of 157.81M shares are outstanding, with a floating share count of 145.54M. Insiders hold about 7.83% of the company’s shares, while institutions hold 98.05% stake in the company. Shares short for IONS as of 1731628800 were 11050361 with a Short Ratio of 6.55, compared to 1728950400 on 9869851. Therefore, it implies a Short% of Shares Outstanding of 11050361 and a Short% of Float of 8.17.
